인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
The human immunodeficiency-1 virus was identified in 1983 as the etiological agent of AIDS. Four years later, the first HIV-1 antiviral drug was approved: the nucleoside analog zidovudine inhibiting the viral reverse transcriptase (RT). Subsequently, non-nucleoside inhibitors of RT, viral protease, viral integrase, and viral entry inhibitors were approved as antiviral drugs. Combining these drugs into a highly active antiretroviral therapy (HAART) decreased the viral load in chronically infected patients and suppressed AIDS defining symptoms. HAART became a medical success story, but the chronic HIV infection cannot be cured by antiviral drugs. Therefore, substantial efforts were undertaken to use antiviral drugs prophylactically to prevent HIV infections in high-risk groups. PreExposure Prophylaxis (PrEP) with oral combined antiretroviral therapy (cART) showed some success in preventing infections in infants born to HIV-infected mothers, decreased the rate of HIV infection in men having sex with men, in women having sex with men, in couples discordant for HIV status and in intravenous drug users. However, the daily burden of pill swallowing compromised seriously the adherence of people to antiviral drugs. The development of injectable long-acting antiviral drugs based on the integrase inhibitor cabotegravir, which needs an injection every 2 months, or the viral capsid inhibitor lenacapavir, injected every half year, showed impressive results in prevention trials with men and women at high risk of infection. The present article describes aspects of HIV antiviral drug development, the outcome of pertinent clinical trials, and discusses economic and political hurdles for injected long-acting antivirals to become a gamechanger for the HIV pandemic.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
